Nutriband Inc. to Officially Launch AI Tape brand in Q1 2023
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has commenced production of its AI Tape brand, with an anticipated launch in Q1 2023. The new product aims to enhance traditional Kinesiology Tape by incorporating therapeutic ingredients in a proprietary adhesive mix. Production is taking place at the company's facility in North Carolina. Nutriband focuses on transdermal pharmaceutical products, developing an abuse deterrent fentanyl patch using its AVERSA™ technology. This aims to prevent drug misuse and accidental exposure.
- Launch of AI Tape in Q1 2023 may enhance product portfolio.
- Manufactured in the USA, ensuring quality control.
- Development of AVERSA™ technology for abuse deterrence adds value.
- Dependence on regulatory approval for product launches.
- Risks associated with competition and market conditions.
ORLANDO, FL / ACCESSWIRE / December 29, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it has begun production of its AI Tape brand with an expected launch of the product line in Q1 2023.
AI Tape is designed to share many of the benefits of traditional Kinesiology Tape. AI Tape further adds soothing and therapeutic ingredients held in suspension with a proprietary adhesive mix.
AI Tape is manufactured in the USA at the Company's Pocono Pharmaceutical facility in North Carolina.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2022 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
Investor Relations
RedChip Companies
Dave Gentry
NTRB@redchip.com
1-800-RED-CHIP (733-2447)
407-491-4498
SOURCE: Nutriband Inc.
View source version on accesswire.com:
https://www.accesswire.com/733546/Nutriband-Inc-to-Officially-Launch-AI-Tape-brand-in-Q1-2023
FAQ
What is the expected launch date for Nutriband's AI Tape?
Where is AI Tape manufactured?
What technology does Nutriband use for its fentanyl patch?
What are the benefits of AI Tape compared to traditional Kinesiology Tape?
What are the potential risks mentioned in Nutriband's press release?
